Abstract
Alustal® and Phostal® are injectable suspensions containing allergen extracts adsorbed onto aluminium hydroxide and calcium phosphate gels, respectively. Alustal® and Phostal® are indicated for use as subcutaneous allergen immunotherapy (SCIT) in children aged ≥5 years and adults who have type 1 allergies of a seasonal or perennial nature. SCIT with Alustal® or Phostal® was effective and generally well tolerated in clinical trials in patients with allergic symptoms induced by grass or tree pollens or house-dust mites. In general, allergic symptoms were improved and the use of symptomatic drug treatment was reduced, with some studies also showing improvements in health-related quality of life. Accelerated Alustal® dose-escalation schedules are available in some countries and will likely improve the convenience of SCIT for patients. Accelerated dose-escalation schedules (e.g. cluster build-up schedules and shortened conventional build-up schedules) were generally well tolerated in clinical trials.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call